Outlook Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
FDA review of the ophthalmic bevacizumab program focused on the NORSE EIGHT trial's missed endpoint, but strong secondary data and prior trial results supported a rapid resubmission. The product is positioned as the first FDA-approved bevacizumab for wet AMD, with a focus on affordability and market access in both the U.S. and Europe.
-
A CRL from the FDA cited insufficient confirmatory efficacy evidence for LYTENAVA in wet AMD, with no other deficiencies. Commercialization in Europe is progressing, especially in Germany and the UK, with break-even expected by early 2026 and a focus on cost conservation.
-
LightNava has launched in Germany and the U.K. with strong initial uptake, national reimbursement, and competitive pricing. Expansion to additional European markets is underway, while a U.S. FDA decision is expected by late August 2025. Healthy margins and further indication expansion are anticipated.
-
The 12-week phase 3 NORSE-8 trial showed ONS-5010 improved visual acuity and reduced retinal thickness in wet AMD patients, demonstrating non-inferiority to ranibizumab. Regulatory resubmission is planned for Q1 2025, with FDA feedback expected by Q3.
Fiscal Year 2024
-
The event detailed progress toward US and EU launches of an ophthalmic bevacizumab, highlighting regulatory exclusivity, strong physician demand, and a focus on quality and cost-effectiveness. Top-line NORSE-8 data is expected in Q4, with a BLA resubmission planned for Q1 next year.
-
Secured first EU and UK approvals for ophthalmic bevacizumab, with U.S. launch targeted for 2025. Clinical trials show strong efficacy and safety, and a payer-driven pricing strategy aims to position the product as a first-line treatment in a $16B global market.
-
Received EU and UK approval for ophthalmic bevacizumab, with European launch planned for H1 2025. U.S. NORSE EIGHT trial enrollment is on track, supporting a BLA resubmission in Q1 2025. Cash and warrant proceeds are expected to fund operations through 2025.